(Q37806309)

23 August 2017

title

Translational advances in pleural malignancies (English)

1 reference

23 August 2017

author

Georgios T. Stathopoulos

series ordinal

1

0 references

publication date

1 January 2011

1 reference

23 August 2017

1 reference

23 August 2017

volume

16

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

53-63

1 reference

Advances in malignant mesothelioma

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Management of malignant pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Prognostic significance of pleural fluid data in patients with malignant effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Screening for malignant mesothelioma--looking for the holy grail

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

A decision tree for differentiating tuberculous from malignant pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Isolation of rare circulating tumour cells in cancer patients by microchip technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Malignant pleural effusions: fixing the leaky faucet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Advances in the systemic therapy of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Animal models of malignant pleural effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Osteopontin is upregulated in malignant and inflammatory pleural effusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Second generation sequencing of the mesothelioma tumor genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Transcriptome sequencing of malignant pleural mesothelioma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Pro-tumorigenic effects of miR-31 loss in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATO

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Thoracic ultrasound in the diagnosis of malignant pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Risk reduction in pleural procedures: sonography, simulation and supervision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

11C-labeled methionine and evaluation of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Pemetrexed safety and pharmacokinetics in patients with third-space fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

An epigenetic mechanism for capecitabine resistance in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Onconase cytotoxicity relies on the distribution of its positive charge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Zoledronic acid is effective against experimental malignant pleural effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

A conditional mouse model for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Tumor necrosis factor-alpha promotes malignant pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

The angiopoietin/Tie2 axis mediates malignant pleural effusion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

CCL2 blockade augments cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Mesothelin-family proteins and diagnosis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2010.01890.X

10.1111/J.1440-1843.2010.01890.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference